GlassScriptPhysician profile
Alan H Chanin
NPI 1174517916
$2,040.80
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $446 · 2021: $571 · 2022: $397 · 2023: $18.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.99 | 2019-2022 | |
| Amgen INC. | $261.80 | 2019-2022 | |
| Lilly USA, LLC | $242.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.15 | 2019-2022 | |
| Pfizer INC. | $148.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $113.23 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.08 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $88.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $79.87 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $74.21 | 2019-2021 | |
| Esperion Therapeutics, INC. | $71.94 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.13 | 2022 | |
| Abbott Laboratories | $61.13 | 2021-2023 | Freestyle Libre 2 |
| Abbvie INC. | $38.99 | 2021-2022 | |
| Amarin Pharma, INC. | $29.88 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.41 | 2019-2021 | |
| Sanofi Pasteur INC. | $27.77 | 2019-2020 | |
| Seqirus USA INC | $26.43 | 2019-2020 | |
| Bausch Health US, LLC | $26.10 | 2021 | |
| Althera Pharmaceuticals LLC | $16.06 | 2021 | |
| Genentech USA, INC. | $15.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.45 | 2021 | |
| Astellas Pharma US INC | $14.44 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.38 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.03 | 2022 | |
| Allergan, INC. | $13.65 | 2020 | |
| Almatica Pharma LLC | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Chanin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.